key: cord-1005710-2lrfqa46
authors: Islam, Mohammad Ariful; Rice, Jamie; Reesor, Emma; Zope, Harshal; Tao, Wei; Lim, Michael; Ding, Jianxun; Chen, Yunhan; Aduluso, Dike; Zetter, Bruce R.; Farokhzad, Omid C.; Shi, Jinjun
title: Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice
date: 2020-10-01
journal: Biomaterials
DOI: 10.1016/j.biomaterials.2020.120431
sha: c130a523fe228812e10e1537af67b009e13e1fe3
doc_id: 1005710
cord_uid: 2lrfqa46

Synthetic mRNA represents an exciting cancer vaccine technology to the implementation of effective cancer immunotherapy. However, inefficient in vivo mRNA delivery along with a requirement for immune co-stimulation present major hurdles to achieving anti-tumor therapeutic efficacy. Here, we demonstrate a proof-of-concept adjuvant-pulsed mRNA vaccine nanoparticle (NP) that is composed of an ovalbumin-coded mRNA and a palmitic acid-modified TLR7/8 agonist R848 (C16-R848), coated with a lipid-polyethylene glycol (lipid-PEG) shell. This mRNA vaccine NP formulation retained the adjuvant activity of encapsulated C16-R848 and markedly improved the transfection efficacy of the mRNA (>95%) and subsequent MHC class I presentation of OVA mRNA derived antigen in antigen-presenting cells. The C16-R848 adjuvant-pulsed mRNA vaccine NP approach induced an effective adaptive immune response by significantly improving the expansion of OVA-specific CD8(+) T cells and infiltration of these cells into the tumor bed in vivo, relative to the mRNA vaccine NP without adjuvant. The approach led to an effective anti-tumor immunity against OVA expressing syngeneic allograft mouse models of lymphoma and prostate cancer, resulting in a significant prevention of tumor growth when the vaccine was given before tumor engraftment (84% reduction vs. control) and suppression of tumor growth when given post engraftment (60% reduction vs. control). Our findings indicate that C16-R848 adjuvant pulsation to mRNA vaccine NP is a rational design strategy to increase the effectiveness of synthetic mRNA vaccines for cancer immunotherapy.

Adjuvant addition has been widely used for various prophylactic vaccines, such as the use of alum in the vaccine formulations for immunization against hepatitis A and B, diphtheria and tetanus, Haemophilus influenzae B, and others [1] . The use of immune stimulants as adjuvants for cancer treatment has also been reported, with the use of Bacillus Calmette-Guérin (BCG) for bladder cancer treatment [2] and interleukins for melanoma [3] as examples. In particular, there is significant interest in understanding how the concurrent stimulation of both the innate and adaptive immune responses can generate effective cytotoxic T cell responses to eliminate tumor cells. Utilizing cancer vaccine strategies is an alternative type of cancer immunotherapy [4] ;

Sipuleucel-T is an example of a dendritic cell (DC)-based vaccine that has been approved for the treatment of prostate cancer [5] . It is worth noting that a significant limitation to functional immunotherapy is the absence of an effective and durable CD8 + T cell-mediated cytotoxic response. Stimulation and expansion of antigen-specific CD8 + T cell populations are often not sufficient to mediate a persistent response and, even in the presence of antigen-specific CD8 + T cells, tumors can persist and grow [6] . To overcome this limitation, it is important to stimulate the innate immune response to unique tumor epitopes in order to generate CD8 + T cells with appropriate effector phenotypes is crucial which is associated with functional therapeutic efficacy and tumor-suppressive outcomes. Effective T cell-mediated immune response can be induced by the careful use of a combination of exposure to antigen along with the co-delivery of immune stimulating adjuvants [7] . mRNA-based therapeutics as well as vaccines hold incredible therapeutic potential and there are currently a number of mRNA-based systems that are progressing to clinical use including mRNA vaccines for COVID-19 [8] [9] [10] [11] [12] [13] [14] [15] . Previous studies have demonstrated the clinical promise J o u r n a l P r e -p r o o f of mRNA for a range of therapeutic applications [8, [16] [17] [18] [19] [20] [21] [22] [23] [24] , proving the utility of mRNA as a powerful immuno-therapeutic platform that can achieve the necessary requirements for safety and scaled-up GMP production [25] . One method used to improve mRNA stability is the modification of mRNA transcripts with alternative naturally occurring nucleotides, such as pseudouridine (Ψ), 5-methylcytidine (5meC) and N1-methylpseudouridine (m1Ψ) [26] [27] [28] [29] [30] .

However, with these modifications, mRNA can become 'immunosilent' and no longer trigger type I interferon (IFN) induction via recognition by toll-like receptor 3 (TLR3), TLR7, and TLR8 [31] . These modifications diminish RNA's self-adjuvant-effect, thus weakening DC activation and subsequent T-cell priming. We propose that incorporating adjuvant pulsation into an anti-tumor vaccine could restore innate immune activation in the context of these synthetic mRNAs and lead to greater immune stimulation [31] .

TLR7 and TLR8 mediate type 1 IFN signaling in response to viral infection [32] [33] [34] .

Synthetic small molecular TLR7/8 agonists from the imidazoquinoline family, including imiquimod and resiquimod (R848), have demonstrated potent anti-tumor immunity and are currently being evaluated in clinical trials [35, 36] . Resiquimod (R848) has been shown to induce immune cell activation and improve therapeutic outcomes when used as an adjuvant in the context of cancer vaccination [37] . In recent work, R848 showed the polarization of tumorassociated macrophages from M2 to M1 phenotype to enhance cancer immunotherapy [38] . The objective of this study was to develop and evaluate a novel vaccine strategy that combines the use of antigen-encoding mRNA with a TLR7/8 agonist, thereby stimulating concurrent innate immune activation to enhance the magnitude and quality of the resulting antigen-specific T cell geneticin was used as an antibiotic (Thermo-Fisher Scientific), and for the HEK-Blue™ TLR cells Normocin, Blasticidin, and Zeocin (InvivoGen) were used as additional antibiotics.

Blasticidin and Zeocin were not added to the media during early passages of HEK-Blue™ TLR cells, only when the cells were beginning to grow well. All biological experiments and cell culture were performed at 37 o C in 5% CO 2 conditions in a cell-culture incubator. Cells authentication (service provided by DDC Biomedical) and mycoplasma contamination were checked before cell experiments in vitro and syngeneic allograft tumor model preparation in vivo.

DC2.4 cells were seeded at a density of 5×10 4 cells per well in 24-well plates and grow until they reached ~80% confluence. Then the cells were transfected with mRNA vaccine NP at varying mRNA concentrations [from 0.100 to 0.700 or 0.300 to 0.500 µg/ml for the cytotoxicity J o u r n a l P r e -p r o o f study of NP (EGFP mRNA) or NP (EGFP mRNA+C16-R848), respectively and from 0.062 to 0.250 µg/ml for the transfection experiment with both NPs] for 16h and then washed with fresh complete medium, followed by further incubation for 24 h to check cytotoxicity and transfection efficiency. An MTT assay was used for NP (EGFP mRNA) and an AlamarBlue assay was employed for NP (EGFP mRNA+C16-R848) to measure cytotoxicity according to the manufacturer's protocols and read using a microplate reader (TECAN, Infinite M200 Pro). To assess the transfection efficiency of the mRNA vaccine NP, cells were collected with trypsin (25% EDTA), washed (2X) and resuspended in PBS. The GFP expression was then measured using flow cytometry and the GFP-positive cell percentages and geometric mean fluorescence intensity (Geo MFI) were calculated using Kaluza Analysis Software and plotted by GraphPad Prism.

To assess C16-R848 activity in the mRNA vaccine NPs, a HEK-blue assay was performed conferring to the company's protocol (InvivoGen). In this protocol, 20 μl of mRNA vaccine NP [without or with C16-R848 termed as NP (OVA mRNA) or NP (OVA mRNA+C16-R848), respectively] and free R848 at various R848 concentrations (10 to 2000 nM) were added to respective wells of a clear flat-bottom 96-well plate in triplicates. The HEK-Blue™ mTLR7 cells were harvested from their cultured flask by gently rinsing cells with pre-warmed 5~10 ml of PBS. 3 ml pre-warmed PBS was added again and the cells were kept at 37˚C for 1~2 min. The cells were then detached from the flask by gentle pipetting (without trypsinization) and made into a homogenize cell suspension for counting. A suspension of cells was prepared in HEK-Blue detection media with a concentration of 220,000 cells per ml and 180 μl of this cell J o u r n a l P r e -p r o o f suspension (~40,000 cells) was immediately added to each well containing the different groups of NP and free R848. The cells were then incubated at 37°C in 5% CO2 for 24 h. The secreted embryonic alkaline phosphatase (SEAP) can be observed and measured at 620-655 nm using a spectrophotometer. The optical density (OD) values of the NP and free R848 groups were normalized using the untreated control cells and the response ratio was presented graphically using GraphPad prism.

DC2.4 cells (at a density of 5×10 4 cells per well) were seeded on 24-well plate and grown until ~80% confluence. Cells were then transfected with OVA mRNA NP (without or with C16-R848) at an mRNA concentration of 0.250 µg/ml for 24 h. L2K-OVA mRNA complex was used as a positive control, and untreated cells and naked OVA mRNA were used as negative controls. J o u r n a l P r e -p r o o f

Mice were immunized with 100 µl PBS containing 30 µg OVA mRNA per mouse as described previously [45] . We calculated that if we use 30 µg of OVA mRNA, mice also received R848 (encapsulated inside the same nanoparticle vaccine formulation) at a concentration of 5.6 µg per mouse, which was quite similar to our previous report [37] .

Mice were anesthetized to collect blood retro-orbitally and then euthanized to aseptically harvest the spleen and tumor-draining lymph nodes (TDLNs) to make single cells using 70 µm strainers (BD Biosciences). In brief, first wet cell strainer by adding 1 ml of cold media on a 50 ml falcon tube followed by placing the spleen or TDLNs on the strainer. Then the organs were gently ground and single cells suspension was made by passing through strainers. The strainer was then washed with 4 ml of cold media to collect the splenocytes. The cells were centrifuged at 250 g for 5 min at RT and the media was aspirated off. The cell pellet was then resuspended using 3 ml of media and the suspension was transferred to a 15 ml falcon tube. To collect peripheral blood mononuclear cells (PBMC) from blood samples, ≥200 µl of blood was collected in heparinized tubes (Fisher Scientific) and immediately diluted with 3 ml of PBS. The mice were immunized as soon as the tumors were first palpated on day 7. Two more immunizations were performed on day 11 and 15. The mice were monitored, and the tumor volume was measured daily after the start of the treatment on day 7. The average tumor size was calculated as (length × width × height). For survival analysis, the mice with tumor volumes over 2200 mm 3 were considered to be dead, and the average percentages of survival were calculated.

The average mouse weight was also determined. The mice were imaged at day 19 post-tumor induction, and Adobe Photoshop software was used to remove the image backgrounds. The mice were sacrificed to evaluate CD8 + T cell and CTL response in spleen and TME.

J o u r n a l P r e -p r o o f

Mice were anesthetized and then euthanized to aseptically harvest tumors. The tumors were kept in ice-cold complete media (RPMI with 10% FBS). The tumors were then bisected using a sharp scalpel. Part of the tumor was kept in 10% formalin (for 2-3 days) followed by storage in 70% ethanol prior to slide preparation for the immunofluorescence testing. And another part of the tumor was taken to isolate myeloid cells to check CD8 + T cell infiltration in TME by flow cytometry. Briefly, each tumor tissue was taken into 2 ml of dissociation buffer (100 U/ml of collagenase IV and 100 µg/ml DNase I in RPMI media with 10% FBS) and kept for 30~40 min at 37 o C. A single cell suspension was made with FACS buffer (PBS with 5% FBS) through 70µm strainer. The resulting suspension was then centrifuged at 400x g for 10 min at 4 o C and then washed one time with FACS buffer. CD8 + T cells were then purified (described in the method section in detail) and counted to take 2 x 10 6 cells per FACS tube for the respective sample. The cells were stained with tetramer (SIINFEKL-H2Kb PE) and CD8a-FITC (BD Biosciences) to determine tetramer + CD8 + T cells by flow cytometry assay. To perform immunohistochemistry assay to further detect CD8 + T cell infiltration in TME, paraffinembedded sections were incubated in xylene for 10 minutes, following rehydration in 100% ethanol three times for 10 minutes each. They were subsequently placed in 95%, 70%, and 50% ethanol for 5 minutes. The rehydration process was then completed by a series of washes in deionized water. The slides were placed into Dako Target Retrieval Solution (Agilent, S1700) and incubated for 30 minutes in a water bath preheated to 98°C. The slides were left to equilibrate for 10 minutes at room temperature and then were cooled down for 10 minutes at 4°C in the Target Retrieval Solution (Agilent). The slides were washed with water and permeabilized J o u r n a l P r e -p r o o f in a solution of 0.1% Triton-X100 in 1X TBS for 15 minutes, followed by further water wash.

The slides were then incubated with a protein blocking solution at room temperature for 30 minutes and then incubated with the primary antibodies (CD8) diluted at 1:200 in Dako Antibody Diluent (Agilent S3022) overnight at 4°C. The next day, the slides were allowed to come to room temperature for 30 minutes followed by washing and incubation with a blocking solution for 10 minutes. They were then incubated for 45 minutes with the secondary antibodies [FITC conjugated Goat Anti-Mouse IgG H&L (Abcam, ab6785) and Alexa Flour 594 conjugated Goat anti-Rabbit IgG (H+L) (ThermoFisher, A11037)] at room temperature. The slides were washed with PBS before being mounted with Vectashield Antifade Mounting Medium with DAPI (Vectorlabs, H-1200). The slides were imaged using confocal microscopy (FV1000 Olympus) immediately or within 4 to 5 days, keeping the slides stored at 4 o C.

GraphPad Prism 7.0 software was used to prepare all graphs and perform statistical analysis, including one-way ANOVA. All experiments were performed in triplicate unless otherwise stated. Error bars indicate standard deviation (SD), unless specified to be standard error means (SEM). A P <0.05 value is considered statistically significant, and all statistically significant values shown in figures are indicated as: *P <0.05, **P <0.01, ***P <0.001, and ****P <0.0001.

In the first set of experiments, we synthesized low molecular weight palmitic acid-conjugated R848 (C16-R848) to enhance the encapsulation efficiency of R848, control its release, minimize J o u r n a l P r e -p r o o f systemic exposure, and provide persistent APC uptake and stimulation with sustained immune surveillance. C16-R848 was synthesized using the Steglich esterification process (Supplementary Figure S1a) . The progress of the reaction was followed using thin-layer chromatography (TLC), and after synthesis, crude was purified using column chromatography. The product was characterized using mass spectrometry (Supplementary Figure S1b Next, a robust self-assembly approach was used to formulate the mRNA NP using C16-R848 and G0-C14, a cationic lipid-like compound [46] , coated with a lipid-poly(ethylene glycol) (lipid-PEG) shell (Fig. 1a) . The G0-C14 was used for EGFP mRNA (used as a model mRNA)

complexation. The G0-C14/EGFP mRNA complexes coated with ceramide-PEG are herein referred to as NP (EGFP mRNA). The addition of C16-R848 during the preparation of NP (EGFP mRNA) makes NP (EGFP mRNA+C16-R848) formulation platform. The stability and integrity of EGFP mRNA, whether naked, complexed with G0-C14, or encapsulated in NPs had no adverse effects in the presence of organic solvent (N, N-dimethyl formamide) (Fig. 1b) . G0-C14 effectively complexed EGFP mRNA at a weight ratio of 5 or above as shown in Fig. 1b. The NPs, prepared at a G0-C14/mRNA weight ratio of 15, showed no leaching of mRNA as analyzed by electrophoresis, indicating that most mRNA (~100%) was entrapped inside the NP.

The NP (EGFP mRNA) was 110.7±1.8 nm in size whereas the size of NP (EGFP mRNA+C16-R848) increased to 137±2.8 nm after C16-R848 loading as characterized by NanoSIGHT. The polydispersity indexes for NP (EGFP mRNA) and NP (EGFP mRNA+C16-R848) were 0.303 and 0.317, respectively. Both the NPs were spherical as revealed by transmission electron J o u r n a l P r e -p r o o f microscopy (TEM) (Fig. 1c-d) . The particle sizes measured in the liquid state by NanoSIGHT ( Fig. 1e) were visually found to be little different from those observed by TEM which were measured in the dry state. At −80 o C storage, the size distribution and morphologies were also characterized using NanoSIGHT and TEM, respectively with no significant differences [NP (EGFP mRNA) was 112.1±2.3 nm and NP (EGFP mRNA+C16-R848) was 144±6.4 nm; and both NPs retained their morphological integrity], suggesting that they are stable in cryo-storage (Supplementary Figure S2) . With an outer lipid-PEG shell, the average surface charges were slightly positively charged; 8.2±0.3 and 11.2±0.21 mV for NP (EGFP mRNA) and NP (EGFP mRNA+C16-R848), respectively, measured by dynamic light scattering (DLS) (Fig. 1e) . We also quantitatively analyzed C16-R848 encapsulation efficacy by high-performance liquid chromatography (HPLC) and found about ~51% C16-R848 encapsulation with this NP formulation which was improved compared to our previous systems [37] as well as other systems reported recently, such as cyclodextrin NPs (~11%) [38] , poly(L-histidine) NPs (23%) [47] , and polylactic acid NPs (~36%) [48] .

The initial priming of T cells to vaccine-derived antigens relies upon antigen processing and presentation by APCs. Here we investigated the safety and transfection activity of the NP (EGFP mRNA) in DCs (DC2.4 cells), the most crucial APC to determine if mRNA introduced by NP delivery resulted in protein expression in this APC cell type. Following 16h transfection and additional 24h incubation, nearly 100% of the cells were viable at different mRNA concentrations from 0.100 to 0.700 µg/ml (Fig. 2a) , indicating that the NP (EGFP mRNA) are not cytotoxic in these cell types. The cytotoxicity of NP (EGFP mRNA) with C16-R848 adjuvant J o u r n a l P r e -p r o o f was also evaluated under similar conditions as described above with a range of mRNA concentrations (from 0.300 to 0.500 µg/ml). We found minimal or no cytotoxic effect within the mRNA concentrations of 0.300 to 0.250 µg/ml and even at the highest mRNA concentration of 0.500 µg/ml, more than 80% cells were found viable (Fig. 2b) . Notably, both NP (EGFP mRNA) and NP (EGFP mRNA+C16-R848) demonstrated a significantly higher transfection efficiency (~95%) in DC2.4 cells even at a lower mRNA dose of 0.062 µg/ml, as validated by the expression of EGFP mRNA and the detection of fluorescent protein expression by flow cytometry (Fig. 2c) . On the other hand, the transfection agent Lipofectamine 2000 (L2K) showed only ~50% transfection capacity even at a high mRNA dose of 0.250 µg/ml (although it is worth noting that the geometric mean fluorescence intensity (Geo MFI) for L2K was significantly higher than all groups including the NP vaccines). This high transfection percentage of NP (EGFP mRNA+C16-R848) in DC2.4 cells suggested that the C16-R848 co-encapsulation did not compromise the bioactivity of the mRNA NP. The transfection efficiency of the mRNA NP was also examined by fluorescence microscopy, which showed enhanced cytosolic GFP expression in DC2.4 cells following treatment with the mRNA NP (Fig. 2d) . Together, these results demonstrated that both NP (EGFP mRNA) and NP (EGFP mRNA+C16-R848) displayed high mRNA transfection efficiency with minimal cytotoxicity in DC2.4 cells.

As a surrogate for vaccine efficacy, we investigated the ability of the C16-R848 mRNA vaccine NP to activate dendritic cells and present OVA mRNA-derived peptides using MHC I, two critical events for facilitating a functional vaccine-mediated immune response. Stimulation J o u r n a l P r e -p r o o f of HEK293 TLR7 reporter cells with R848 or C16-R848 mRNA NP resulted in increased reporter cell activity in a dose-dependent manner. TLR7 activity of the NP (OVA mRNA+C16-R848) and free R848 treatment groups was significantly higher than the response to NP (OVA mRNA) control (without C16-R848) (Fig. 3a) . This result suggested that NP (OVA mRNA+C16-R848) retained TLR7 agonist activity and could provide a functional adjuvant activity via the encapsulated C16-R848.

To assess the ability of NPs to facilitate MHC class-I presentation of peptide epitopes in DCs Figure S3b) . Particularly, the antigen-specific CD8 + T cells response by NP (OVA mRNA+ C16-R848) was significantly higher compared to NP (OVA mRNA). These results suggest that this vaccination strategy can induce an antigen-specific T cell response and the addition of C16-R848 may further improve the potency of the vaccine NP system.

We next investigated the in vivo prophylactic efficacy of NP (OVA mRNA+C16-R848) in an EG.7-OVA-bearing syngeneic allograft tumor model. Mice were vaccinated 25, 11 and 4 days prior to tumor inoculation into the right flank of C57BL/6 immunocompetent mice (n = 4 or 5 mice) (Fig. 4a) . The tumor growth inhibitions observed in NP (OVA mRNA) and NP (OVA mRNA+C16-R848) treated mice were significantly greater than that of the controls, NP (EGFP mRNA+C16-R848) and PBS treated groups on day 19 post tumor induction (Fig. 4b-e) .

Specifically, the average tumor sizes rapidly increased in controls, reaching mean volumes of J o u r n a l P r e -p r o o f ~1044 mm 3 

and PBS groups, respectively. This is significantly higher than the mean volume of ~202 mm 3 for NP (OVA mRNA) and only ~48 mm 3 for NP (OVA mRNA+C16-R848) treatment groups measured at day 19 post tumor induction (Fig. 4c) . After day 19 post tumor induction, tumor growth for NP (OVA mRNA) without adjuvant exponentially increased over the investigated period (reached to ~900 mm 3 ), whereas the NP (OVA mRNA+C16-R848) group continued to suppress tumor growth significantly till day 27 (reached to ~208 mm 3 ) (Fig. 4c-d) Figure S4a) . To check for CD8 + T cells infiltration in TME after immunization with NP (OVA mRNA+C16-R848) vs.

PBS or NP (EGFP mRNA+C16-R848) or NP (OVA mRNA), tumor sections were analyzed after CD8 antibody staining. A significantly increased level of CD8 + T cell infiltration was observed for the NP (OVA mRNA+C16-R848) treatment group relative to that of the PBS or NP (EGFP mRNA+C16-R848) or NP (OVA mRNA) groups ( Fig. 5a-b) , validating the mechanism of action by NP (OVA mRNA+C16-R848) vaccination in preventing tumor growth. Mice body weight did not undergo significant changes for any of the group, suggesting toxicity was not an issue (Supplementary Figure S4b) .

To investigate the in vivo therapeutic efficacy of NP (OVA mRNA+C16-R848), RM1-OVA syngeneic allograft tumor models were prepared by s.c. injection of RM1-OVA mouse prostate cells into the right flank of C57BL/6 immunocompetent mice (n=4 or 5). The mice were immunized on day 7 upon the development of palpable tumors and immunizations were repeated at days 11 and 15 (Fig. 6a) . In therapeutic settings, tumor growth was much more aggressive.

Similarly to the prophylactic model, the average tumor size increased to ~2,115 mm 3 and ~2,482 mm 3 for the NP (EGFP mRNA+C16-R848) and PBS controls, respectively, while the NP (OVA mRNA+C16-R848) treatment significantly limited the tumor growth to a mean size of ~965 mm 3 , which was also significantly lower compared to the mean size of ~1,847 mm 3 by NP (OVA J o u r n a l P r e -p r o o f mRNA) vaccinated group (Fig. 6b-d) . Specifically, NP (OVA mRNA) failed to show any immunotherapeutic effect to suppress tumor growth, whereas NP (OVA mRNA+C16-R848) group exhibited tumor suppression capacity throughout the study period, indicating a robust therapeutic efficacy to the C16-R848 adjuvant-pulsed mRNA vaccine NP platform and it's significant potential for initiating tumor-specific responses to neo-antigens in vivo. Tumor size of the individual mice from each separate group was shown in Fig. 6d . Moreover, we further monitored for CD8 + T cell infiltration in TME in this therapeutic tumor model after immunization with NP (OVA mRNA+C16-R848) vs. PBS or NP (EGFP mRNA+C16-R848) or NP (OVA mRNA) group. On day 15, two mice from PBS, NP (EGFP mRNA+C16-R848), and NP (OVA mRNA+C16-R848) groups and one mouse from NP (OVA mRNA) group were euthanized and tumors were collected to analyze CD8 + T cell infiltration in TME by flow cytometry. Tumors were collected and CD8 + T cells were isolated and then purified (described in the method section in detail). The cells were stained with tetramer SIINFEKL-H2K b PE and CD8a-FITC (BD Biosciences) to determine tetramer + CD8 + T cells by flow cytometry assay.

Supplementary Figure S5 showed a trend of an increased level of tetramer + CD8 + T cells by NP (OVA mRNA+C16-R848) group compared to that by PBS, NP (EGFP mRNA+C16-R848) or NP (OVA mRNA) group. Moreover, CD8 + T cells in TME were further evaluated by immunohistochemistry at the terminal days. In this experiment, mice were sacrificed and tumor sections were analyzed after CD8 antibody staining. NP (OVA mRNA+C16-R848) treatment group showed a significantly increased level of CD8 + T infiltration compared to that of the PBS, NP (EGFP mRNA+C16-R848) or NP (OVA mRNA) groups ( Fig. 7a-b) . Note that the mouse body weight had no significant change between the vaccinated groups (Supplementary Figure   S6 ).

The development of effective and durable anti-tumor immunity relies on the initial priming of the adaptive immune activity via the proliferation of antigen-specific cytotoxic T cells [50] [51] [52] . Current vaccination approaches to stimulating this response are complicated by the need for the adoptive transfer of ex vivo antigen-loaded dendritic cells [53, 54] . The de novo expression of exogenous mRNA delivered via NPs allows antigen-presenting cells to be preferentially transfected and results in the increased presentation of tumor-associated neo-antigens. When these APCs are concomitantly stimulated through pathogen recognition receptors (PRRs) including TLR7/8, MHC-I antigen presentation is further increased and stimulates a more robust CD8 + T cell response [55] . Resiquimod (R848) is a TLR7/8 agonist that is used as an adjuvant, in part for its ability to increase antigen-specific CD8 + T cell expansion and impede tumor growth [56] . In this report, we present a stable NP platform for the co-delivery of synthetic OVA mRNA as a model antigen and C16-R848 as a modified TLR7/8 agonist (Supplementary Figure   S1 and Fig. 1 ). The delivery platform was conceptualized from a new-generation polymer-lipid hybrid NP system reported in our recent work [9] that demonstrated effective systemic delivery of tumor suppressor mRNA to various tumor models in vivo resulting in a significant prophylactic and therapeutic anti-tumor effect. In the present study, we prepared a nanovaccine formulation using the lipid-like material G0-C14 to encapsulate both mRNA antigen and C16-R848 coated with lipid-PEG (i.e., ceramide-PEG) and to be efficiently taken up by the antigenpresenting cells (APCs). To accelerate the de-PEGylation kinetics and subsequent cellular uptake of the NPs, we chose to use ceramide-PEG [57, 58] . This approach prevents agglomeration, enabling re-distribution after freezing and offering the baseline stability required for synthesis J o u r n a l P r e -p r o o f and storage, while also providing rapid dissociation kinetics in vivo. Once inside the cell, these NPs show proton sponge effect, releasing the cargo into the cytosol of the cell. Within the APC, the C16-R848 and OVA mRNA act synergistically to increase MHC I mediated antigen presentation. First, the OVA mRNA is translated into the OVA protein where it is processed by the immunoproteasome, allowing efficient presentation of antigen by the APC to CD8 + T cells.

The C16-R848 adjuvant supplements this immune response in two ways: first, the C16 (palmitic acid) stabilizes the OVA peptide on the APC during antigen presentation [59, 60] and second, the C16-R848 activates TLR7/8 expressing APCs, activating a type 1 IFN response and upregulating the pathways responsible for antigen presentation. mRNA delivery can be achieved via DC transfection ex vivo followed by re-engraftment in vivo [61] or via mRNA delivery in vivo, with or without the use of a delivery vehicle. Although ex vivo manipulation of DCs with mRNA provides increased control of the transfection process and cellular conditions, its potential as a clinical therapy is hindered by the sub-optimal efficacy of re-engraftment and the prohibitive resource requirement. Conversely, the administration of mRNA in vivo is simpler. However, it requires a vehicle to transfect immune cells and increase antigen presentation efficiently. Delivery methods involving gene guns [62] , in vivo electroporation [63] and in vivo administration of naked mRNA have been evaluated previously [64] , but are not effective in delivering mRNA to immune cells, leading to suboptimal immune responses [65] . Cationic lipid and polymer-based delivery systems are favorable for transfection, because their properties can be tuned using different formulation chemistries to modulate interaction behavior. Protamine-based mRNA vaccine systems are an example of a cationic peptide delivery platform that has demonstrated significant T cell and B cell stimulation resulting in enhanced levels of cellular immunity and anti-tumor effect in clinical trials [66] . in DC2.4 cells either with or without C16-R848 pulsation while maintaining cell viability from 80%~100% depending on the mRNA NP concentrations (Fig. 2) .

In addition to mRNA delivery, adjuvant delivery is a critical component of a vaccine formulation. Adjuvants can improve immune responses by activating APCs to increase antigen presentation (signal 1), promote the co-expression of costimulatory molecules (signal 2) and the production of specific cytokines (signal 3) that, when properly coordinated, enhance T cell responses [68] . Adjuvants currently approved for human use in Europe and the United States include aluminum salts, oil-in-water emulsions as well as TLR4 and TLR9 adjuvants [69] .

Aluminum salts and oil-in-water emulsions are the most commonly used, however they are limited by their need for repeated administration in order to induce protection [55] . On the other hand, the most effective adjuvants for cancer vaccines are those that target and activate TLRs.

Common adjuvants are detoxified congener endotoxins [70] and monophosphoryl lipid A J o u r n a l P r e -p r o o f (MPLA) [7] which stimulate TLR4 used by the immune system to recognize pathogen-associated molecular patterns, enabling for immune responses specific to particular stimuli. TLR9 agonists, oligonucleotides (ODN) containing unmethylated CpG sequences, have also proven successful in promoting Th1 versus Th2 effector T cell responses, and have been implemented as adjuvants in approved vaccines [71] . In this context, TLR7/8 agonists have been rapidly gaining traction due to their ability to stimulate strong T cell responses [72] . The TLR7/8 agonist R848 induces DC maturation, stimulates pro-inflammatory cytokines production and enhances humoral and cellular adaptive immunity [73] . In a recent study, R848-loaded β-cyclodextrin NPs inhibited tumor growth in multiple tumor models through the conversion of the immunosuppressive M2 macrophage phenotype to the M1 that is associated with positive clinical outcomes [38] .

Additionally, co-delivery of lipopolysaccharide (LPS) with R848 induced the generation of a spectrum of DC maturation phenotypes, including less mature DCs that are required for the generation of an effective memory CD8 + T cell response [74] . Administration of R848 also showed tumor growth inhibition >50% when used in combination with taxol-based chemotherapy to treat primary human colorectal xenografts in mice [75] .

In this study, we used a modified version of R848 called C16-R848 synthesized by conjugating palmitic acid (C16) to R848 for having more stable co-encapsulation of this adjuvant into the mRNA NP. To evaluate the effect of C16-R848 activity in vitro, a cell-based reporter measuring NF-kb and AP-1 activation was used following exposure to C16-R848 encapsulated in NPs or freely dissolved in media. In this system, the cell response to C16-R848 (coencapsulated in mRNA NP) compared with free R848 was similar (Fig. 3a) , suggesting that NP (OVA mRNA+C16-R848) retained R848 activity. To further test whether incorporation of C16- The co-delivery of mRNA and C16-R848 in a NP as a cancer vaccine strategy has not been previously reported, although attempts have been made previously to achieve similar results. In a recent report, a charge-altering releasable transporter (CART) NP delivery system was used to deliver OVA mRNA in combination with CpG (a synthetic DNA molecule which is short, single-stranded and contains a cytosine triphosphate deoxynucleotide followed by a guanine triphosphate deoxynucleotide) in an A20-OVA lymphoma syngeneic allograft model, resulting in complete regression of the tumor which extended survival beyond 75 days, indicating the establishment of a durable anti-tumor immune response [76] . In this CART-OVA mRNA study, the treatment increases cytotoxic T cell responses and the tumor-specific killing capacity. This also aligned with the results presented in our study where we found higher CD8 + T cell response in the NP (OVA-mRNA+C16-R848) treated mice compared to that of control groups, naked OVA mRNA, NP (C16-R848) as well as NP (OVA mRNA) (Fig. 3c) . In another approach, a DOTAP-cholesterol lipoplex NP was utilized in a co-delivery system, loaded with J o u r n a l P r e -p r o o f monophosphoryl lipid A (MPLA, a TLR4 agonist which is an FDA approved vaccine adjuvant) and nucleoside-modified OVA mRNA [31] . In this study mRNA was modified with 5'methylcytidine and pseudouridine to increase the translational potential of the mRNA lipoplexes, however this modification reduced the stimulation of type I IFN release and overall immunoactivity of the mRNA. To improve the efficacy of the vaccine platform, MPLA was codelivered to compensate for the reduction in immune activity due to the modification of the mRNA. Although this study hypothesized that the MPLA-OVA mRNA co-delivery vaccine platform is a feasible system for safe vaccine platform, it did not demonstrate anti-tumor efficacy. In our study, however, we found a high CD8 + T cell response by NP (OVA mRNA+C16-R848) system provoked both prophylactic and therapeutic efficacy, resulting in an 84% reduction of tumor volume when used as a prophylactic treatment and a 60% reduction when administered therapeutically after establishment of palpable tumors (~ 100 mm 3 ) in the EG7-OVA lymphoma and RM1-OVA prostate cancer allograft models, respectively ( Fig. 4 and   Fig. 6 ).

In addition to the initial activation and expansion of an antigen-specific CD8+ T cell population, subsequent T cell infiltration into the tumor is essential for positive therapeutic outcomes, especially in the context of immune checkpoint therapy [77] [78] [79] . In our prophylactic study, treatment with the NP (OVA mRNA+C16-R848) significantly stimulated an antigenspecific CD8 + T cell response. This response was further differentiated by the subsequent antigen-specific CD8 + T cell infiltration within the tumor bed in mice by NP (OVA-mRNA+C16-R848) vaccine, compared with PBS, NP (EGFP-mRNA+C16-R848) or NP (OVA-mRNA) (Fig. 5) . The CD8 + T cell infiltration correlated with a reduction in tumor size, suggesting that effective tumor control relies on both expansion and infiltration of the tumor J o u r n a l P r e -p r o o f antigen specific CD8+ T cell population. The therapeutic treatment following establishment of the tumor also indicates that NP (OVA mRNA+C16-R848) can control tumor progression to a greater extent than controls as well as NP (OVA-mRNA) without adjuvant pulsation and this tumor prevention was correlated with the increased infiltration of CD8 + T cells at the TME site ( Fig. 7 and Supplementary Figure S5) . Overall, we found that the antigen-specific CD8 + T cell population in the NP (OVA mRNA+C16-R848) group infiltrated and proliferated at the TME site, likely due to improved effector function. The increased effector function was presumably because they were well primed due to increased antigen-presentation at the APC surface and/or also present a co-stimulatory TLR7/8 mediated co-activation of the antigen presenting cell, wherein all these were deficient for the NP (OVA mRNA) group without the adjuvant pulsation.

Together, these results demonstrate that the addition of C16-R848 adjuvant pulsation to the mRNA nanovaccine can enhance the efficacy of synthetic mRNA as a source of antigen to trigger a therapeutic CD8 + T cell-mediated anti-tumor response.

In summary, this study is a proof-of-principle for the development of a vaccine using a NP encapsulating a synthetic mRNA antigen and the chemically-modified TLR7/8 agonist C16-R848. The co-delivery of the C16-R848 adjuvant with OVA mRNA improved the vaccine's therapeutic and prophylactic efficacy by increasing the tumor-associated antigen (TAA) presentation, while also promoting CD8 + T cell recruitment into the tumor and enhancing the overall anti-tumor response. The NP strategy resulted in a high mRNA transfection efficiency which led to a robust antigen specific CD8 + T cell population and observable tumor infiltration.

The efficiency of this vaccine platform could potentially be further improved through additional J o u r n a l P r e -p r o o f use of immune checkpoint inhibitors including anti-PD-1 that can downregulate inhibitory immune signaling in the TME, reducing tumor cell immune tolerance and increasing T cellmediated anti-tumor activity [80] . The versatility of this mRNA nanovaccine platform allows for the encapsulation and delivery of other TAA-encoding mRNA payloads, having the potential to expand potential indications to a wide range of diseases. Recent progress in the field of tumor associated T-cell epitope prediction [81] makes this especially exciting, opening up the potential to easily facilitate the presentation of multiple tumor associated T cell epitopes on activated resident antigen-presenting cells, without the requirement for DC-meditated antigen crosspresentation. Robust peripheral expansion of antigen-specific effector CD8 + T cells has the potential to overcome some of the limitations of immune checkpoint therapy where a lack of T cell expansion and infiltration hinders the clinical efficacy. Figure S5 for the result). In addition, note that one mouse died on day 15 from the PBS group. Error bars represent the s.e.m. and significance was determined using One-Way ANOVA test (*P<0.05 and **P<0.01).

Immunohistochemistry to further confirm in vivo CD8 + T cell infiltration in the TME for the mice investigated in immunotherapeutic settings (see scheme in Figure 6a ). Mean fluorescent intensity (MFI) was measured using ImageJ software and plotted with GraphPad prism. PBS and NP (EGFP mRNA+C16-R848) groups were used as controls. Error bars represent the s.d. and significance was

Aluminum salts in vaccines-US perspective

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma

The cancer vaccine roller coaster

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

The blockade of immune checkpoints in cancer immunotherapy

Key roles of adjuvants in modern vaccines

Tools for translation: non-viral materials for therapeutic mRNA delivery

Restoration of tumourgrowth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Synthetic mRNA nanoparticlemediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination

Biomedical applications of mRNA nanomedicine

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes

Cancer immunotherapy with mRNA-transfected dendritic cells

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells

Telomerase mRNAtransfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma

mRNA cancer vaccines-messages that prevail. Cancer Vaccines: Springer

Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L

N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

Codelivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA

Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-α and type 1 IFNs after feeding a TLR7/8 ligand

A distinct subset of intestinal dendritic cells responds selectively to oral TLR7/8 stimulation

High-avidity antitumor Tcell generation by toll receptor 8-primed, myeloid-derived dendritic cells is mediated by IL-12 production

Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial

A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1

Adjuvantcarrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation

Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy

Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy

Lipidation Approaches Potentiate Adjuvant-Pulsed Immune Surveillance: A Design Rationale for Cancer Nanovaccine

Nucleosidemodified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy

Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors

Neoantigens in cancer immunotherapy

Towards personalized, tumour-specific, therapeutic vaccines for cancer

Tumor neoantigens: building a framework for personalized cancer immunotherapy

Personalized vaccines for cancer immunotherapy

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma

Surface De-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo

Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment

Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells

Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships

mRNA-based dendritic cell vaccines

Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP. TRP2

Intradermal electroporation of naked replicon RNA elicits strong immune responses

Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format

mRNA vaccines-a new era in vaccinology

Biomaterials for mRNA delivery

Kinetics of mRNA delivery and protein translation in dendritic cells using lipid-coated PLGA nanoparticles

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings

Use of defined TLR ligands as adjuvants within human vaccines

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Novel immune potentiators and delivery technologies for next generation vaccines

Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28

Combinations of TLR ligands: a promising approach in cancer immunotherapy

mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice

Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety

Anticancer drugs: Translational target for checkpoint inhibitors

Translational target for checkpoint inhibitors

mRNA Vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma

Immunoinformatics and epitope prediction in the age of genomic medicine